220 related articles for article (PubMed ID: 30715424)
41. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
42. Treatment of follicular lymphoma.
Izutsu K
J Clin Exp Hematop; 2014; 54(1):31-7. PubMed ID: 24942944
[TBL] [Abstract][Full Text] [Related]
43. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Kahl BS; Hong F; Williams ME; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ
J Clin Oncol; 2014 Oct; 32(28):3096-102. PubMed ID: 25154829
[TBL] [Abstract][Full Text] [Related]
44. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.
Maloney DG
Hematology Am Soc Hematol Educ Program; 2007; ():226-32. PubMed ID: 18024634
[TBL] [Abstract][Full Text] [Related]
45. Rituximab as maintenance therapy for patients with follicular lymphoma.
Vidal L; Gafter-Gvili A; Leibovici L; Shpilberg O
Cochrane Database Syst Rev; 2009 Apr; (2):CD006552. PubMed ID: 19370640
[TBL] [Abstract][Full Text] [Related]
46. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
47. Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
Budau L; Wilhelm C; Moll R; Jäkel J; Hirt C; Dölken G; Maschmeyer G; Neubauer E; Strauch K; Burchert A; Herold M; Neubauer A
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2149-2156. PubMed ID: 31273513
[TBL] [Abstract][Full Text] [Related]
48. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
Nabhan C; Smith SM; Kahl BS
Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
[TBL] [Abstract][Full Text] [Related]
49. [Follicular lymphoma].
Tomita N
Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
[TBL] [Abstract][Full Text] [Related]
50. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas.
Karmali R; Kimby E; Ghielmini M; Flinn IW; Gordon LI; Zucca E
Ann Oncol; 2018 Feb; 29(2):332-340. PubMed ID: 29206891
[TBL] [Abstract][Full Text] [Related]
51. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
52. Current status and perspective of antibody therapy in follicular lymphoma.
Buske C; Weigert O; Dreyling M; Unterhalt M; Hiddemann W
Haematologica; 2006 Jan; 91(1):104-12. PubMed ID: 16434378
[TBL] [Abstract][Full Text] [Related]
53. [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
Koch R; Sander CA
Hautarzt; 2010 Nov; 61(11):976-9. PubMed ID: 20221574
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
Al-Salman J; Salib H; Boonswang P
Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454
[TBL] [Abstract][Full Text] [Related]
55. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
56. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
57. Current and future therapeutic approaches for the treatment of follicular lymphoma.
Pulsoni A; Cappelli LV; Ballotta L; Canichella M; Serrao A; Annechini G; D'Elia GM; Foà R
Expert Rev Anticancer Ther; 2018 Sep; 18(9):931-941. PubMed ID: 29972084
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of rituximab in follicular lymphoma.
Johnston KM; Bolbocean C; Connors J; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
[TBL] [Abstract][Full Text] [Related]
59. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
60. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
